Whitney Graybill, MD
Gynecologic Oncology · Charleston, SCNPI 1851550305
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (53.3%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 10 manufacturers reported payments, led by Eisai Inc. at 46.5% of the total. 2025 is the largest year on record at $37,905, 6.9 times the $5,507 reported in 2019.
Across 91 payments — averaging $894.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eisai Inc.$38K
- GSK$22K
- AstraZeneca$13K
- Tesaro, Inc.$5K
- Clovis Oncology, Inc.$2K
- Medtronic$1K
- plus $431 from 4 others
Across 65 payments — averaging $6722.65 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$214K
- Merck$119K
- AbbVie$42K
- Tesaro, Inc.$29K
- Corcept Therapeutics$25K
- Seagen Inc.$7K
What the payments were for
- Consulting fees$26,13332%
- Speaking & faculty fees$43,37553%
- Travel & lodging$9,27911%
- Food & beverage$2,4253%
- Education$1770%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eisai Inc. | 30 | $37,840 |
| GSK | 13 | $22,197 |
| AstraZeneca | 8 | $12,590 |
| Tesaro, Inc. | 20 | $5,435 |
| Clovis Oncology, Inc. | 1 | $1,700 |
| Medtronic(2 entities) | 14 | $1,195 |
| Myriad Genetic Laboratories, Inc. | 2 | $233 |
| Merck | 1 | $119 |
| Genentech USA, Inc. | 1 | $53 |
| Johnson & Johnson | 1 | $27 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few gynecologic oncology providers in South Carolinato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 15 | $11,640 |
| Dexamethasone | 27 | $518 |
| Letrozole | 14 | $307 |
| Duloxetine Hcl | 24 | $297 |
| Prochlorperazine Maleate | 23 | $265 |
| Ondansetron Hcl | 38 | $206 |
| Amlodipine Besylate | 18 | $87 |
Paid to pharmacies, not to this prescriber.
Other gynecologic oncology in Charleston
- Courtney BaileyCharleston$5K
- Jonathan FooteCharleston$3K
- Catherine WatsonCharleston$3K
- Brian OrrCharleston$3K
- Ward KatsanisCharleston$1K
- Thomas JenningsCharleston$1K
- David MysonaCharleston$73
- William MerrittColumbia$9K
- Mark MillerWest Columbia$8K
- James WilliamsColumbia$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.